腹膜透析联合血液透析治疗终末期肾病临床应用探讨.docVIP

腹膜透析联合血液透析治疗终末期肾病临床应用探讨 　　【摘要】 目的：探讨腹膜透析联合血液透析治疗终末期肾病的作用。方法：选择2012年5月-2014年5月于本院住院的诊断为终末期肾病的患者90例作为研究对象。将其分为联合组、腹膜透析组和血液透析组三组，每组30例。随访1年，观察三组患者住院期间的各项生化指标、并发症发生情况，并统计所有患者一年内的生存率和死亡原因，并根据KDQOL-SFTM 1.2生存质量评分表对存活患者的生存质量进行分析。结果：联合组患者血钾、血糖水平与腹膜透析组和血液透析组比较差异无统计学意义（P0.05）；联合组尿素氮和肌酐水平与血液透析组比较差异无统计学意义（P0.05），与腹膜透析组比较明显降低，差异有统计学意义（P0.05）。联合组患者并发症总发生率明显少于腹膜透析组和血液透析组，差异有统计学意义（P0.05）。联合组患者症状与不适12项、日常生活的影响8项、工作状况2项、社交质量3项、性功能2项、社会功能2项、精力状况4项较腹膜透析组和血液透析组有明显改善，差异有统计学意义（P0.05）。结论：联合透析能够稳定患者的内环境状态，效果好，并发症少，值得临床推广应用。 　　【关键词】 腹膜透析联合血液透析； 终末期肾病 　　【Abstract】 Objective：To investigate the therapeutic effect of combination of peritoneal dialysis and hemodialysis for end-stage renal disease.Method： 90 patients of end-stage renal disease were selected in our hospital as the research object from May 2012 to May 2014 and divided into three groups，combination group， peritoneal dialysis group and hemodialysis group， 30 cases in each group. One year follow-up，the three groups of patients’ complications ，biochemical indexes during hospitalization，and statistics of all patients with in one year survival rate and cause of death were observed， according to the quality of life of 1.2 KDQOL-SFTM scores of quality life on the survival of patients with analysis.Result：There were not statistically significant differences between combination group and peritoneal dialysis group and hemodialysis group in serum potassium and blood glucose level（P0.05）. The combination group of urea nitrogen and creatinine levels compared with hemodialysis group had no significant difference（P0.05），and compared with peritoneal dialysis group significantly decreased， the difference was statistically significant（P0.05）.The rate of complication in the combination group was significantly less than peritoneal dialysis group and hemodialysis group，the difference was statistically significant（P0.05）.The combination group patients symptoms and discomfort of 12 items， affect daily life of 8 items， the working condition of 2 items，